Abstract 432P
Background
Although extravasation (EV) is an established complication of parenteral chemotherapy, it often goes under-documented and underestimated. The incidence and severity of extravasation can be influenced by patient, drug or procedure related factors. An understanding of the risk factors and predictors promotes precaution during chemotherapy.
Methods
A prospective study was conducted for one year in patients satisfying study criteria. Patient information such as demographics, history, disease, treatment regimen and EV related information was documented. Severity of EV was established using CTCAE 4.3. The captured data was subjected to appropriate statistical analysis using SPSS ver. 20.
Results
Amongst the 217 patients reviewed 46(21.20%) experienced EV [Grade 2(67.39%) and Grade 3(32.61%)]. Cluster statistics revealed age, gender and ambulation to be the most important predictors. Ambulation caused an 8 fold increase in the risk of EV (p < 0.001, [2.01-14.2]). Females were observed to be 2.5 times susceptible to EV (p = 0.001, [2.5-5.9]) than males. Progressive age i.e. beyond 60 years the risk of EV increases 2.02 times (p = 0.005, [1.3-3.8]). Additionally, age (p = 0.007, OR: 2.24 [1.22-6.71]), sex (p = 0.010, OR: 2.71 [1.38-7.64]), ambulation (p = 0.001, OR: 4.67 [2.09-4.90], co-morbidities (p = 0.029, OR: 3 [2.17-5.67] and the use of irritants (p = 0.007, OR: 2.25 [1.27-3.76] increased the risk of the patient getting severe EV injury.
Conclusions
Patient, drug and procedure related risk factors influence the incidence of chemotherapy induced EV injury. In the studied population, age, gender, ambulation and co-morbidities were established as predictors of extravasation. Multi-disciplinary approach and patient counselling can contribute to minimizing the discomfort and complication of EV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
All Authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract